MAP2K7 and cancer: Our preclinical study demonstrates that combining PLK1 inhibitors with EGFR/MEK/ERK pathway inhibitors not only exhibits remarkable efficacy in eradicating cancer cells but also effectively overcomes the acquired resistance to EGFR-TKIs, thus offering a potential clinical treatment strategy for EGFR-mutant NSCLC patients.